|本期目录/Table of Contents|

[1]王毅,权琳.培美曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):43-47.[doi:10.3969/j.issn.1672-271X.2020.01.010]
　WANGYi,QUANLin.Effects of pemetrexed and cisplatin combined with gefitinib on T cell subsets and cytokines in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(01):43-47.[doi:10.3969/j.issn.1672-271X.2020.01.010]
点击复制

培美曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年01期
页码:
43-47
栏目:
临床研究
出版日期:
2020-01-06

文章信息/Info

Title:
Effects of pemetrexed and cisplatin combined with gefitinib on T cell subsets and cytokines in patients with lung cancer
作者:
王毅; 权琳
作者单位：210029 南京，南京市胸科医院呼吸科（王 毅、权 琳）
Author(s):
WANG　Yi;  QUAN　Lin
（Department of Respiration，Nanjing Chest Hospital,Nanjing 210029，Jiangsu，China）
关键词:
培美曲塞; 顺铂; 吉非替尼; 非小细胞肺癌; T细胞亚群; 细胞因子
Keywords:
pemetrexed;  cisplatin;  gefitinib;  lung cancer;  T cell subsets;  cytokines
分类号:
R734.2
DOI:
10.3969/j.issn.1672-271X.2020.01.010
文献标志码:
A
摘要:
目的　探究培美曲塞与顺铂联合吉非替尼治疗非小细胞肺癌患者的效果，以及对T细胞亚群及细胞因子的影响。 方法　回顾性分析2017年1月至2018年12月南京市胸科医院收治的84例非小细胞肺癌患者临床资料，依据治疗方式的不同分为吉非替尼组、培美曲塞联合顺铂组以及三药联合组（给予培美曲塞与顺铂联合吉非替尼治疗），每组各28例。比较3组患者治疗前后的免疫功能(CD3+、CD4+、CD8+、CD4+/CD8+、CD4+/CD25+)、细胞因子水平[白细胞介素-2（IL-2）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）以及γ干扰素（IFN-γ）]，以及治疗后的不良反应发生情况。 结果　三药联合组治疗后CD3+[（65.1±9.0）%]、CD4+[（36.3±7.2）%]以及CD4+/CD8+（1.9±0.5）水平分别与吉非替尼组[（55.3±6.4）%、(26.5±9.1）%、(1.1±0.2）]、培美曲塞联合顺铂组[（57.8±6.9）%、(27.2±9.4）%、(1.2±0.3）]比较显著升高（P<0.05），3组患者的CD8+、NK以及CD4+/CD25+水平比较差异无统计学意义（P>0.05）；三药联合组治疗后的IL-2[（5.6±2.6）pg/mL]、TNF-α[（6.1±2.9）pg/mL]以及IFN-γ[（13.2±3.5）pg/mL]水平分别与吉非替尼组[（3.3±2.3）pg/mL、（4.6±2.4）pg/mL、（9.5±2.8）pg/mL]、培美曲塞联合顺铂组[（3.5±2.4）pg/mL、（4.9±2.6）pg/mL、（10.2±3.0）pg/mL]比较显著升高（P<0.05），IL-6[（13.2±8.1）pg/mL]及IL-10[（5.1±3.2）pg/mL]水平与吉非替尼组[（18.2±6.9）pg/mL、（6.2±3.5）pg/mL]、培美曲塞联合顺铂组[（17.3±7.0）pg/mL、（6.5±3.8）pg/mL]比较显著降低（P<0.05）；三药联合组不良反应的总发生率（21.4%）显著低于吉非替尼组（57.1%）和培美曲塞联合顺铂组（42.9%），差异有统计学意义（P<0.05）。 结论　对非小细胞肺癌患者采用培美曲塞与顺铂联合吉非替尼治疗，有助于改善患者的T细胞亚群以及细胞因子的水平，不良反应较少，可帮助患者改善其症状。
Abstract:
Objective　To explore the effect of pemetrexed combined with cisplatin and gefitinib in the treatment of non-small cell lung cancer (NSCLC)，and the effect on T cell subsets and cytokines.　Methods　The clinical data of 84 patients with non-small cell lung cancer received from January 2017 to December 2018 were retrospectively analyzed. According to the different treatment methods，they were divided into study group，gefitinib group and pemetrexed combined with cisplatin group，with 28 patients in each group. The control group was treated with gefitinib alone，while the control group was treated with pemetrexed combined with cisplatin. The study group was treated with pemetrexed plus cisplatin combined with gefitinib. The immune function，cytokine levels and the occurrence of toxic and side effects were compared between the three groups before and after treatment.　Results　After treatment，the levels of CD3+ [(65.1±9.0)%]，CD4+ [(36.3±7.2)%] and CD4+/CD8+ (1.9±0.5) in the study group were significantly higher than those in the control group [(55.3±6.4)%，(26.5±9.1)%，(1.1±0.2)] and the control group [(57.8±6.9)%，(27.2±9.4)%，(1.2±0.3)]，respectively (P<0.05). There was no significant difference in the levels of CD8+，NK，CD4+/CD25+ (P>0.05) between the three groups. After treatment，the levels of IL-2 [(5.6±2.6）pg/mL]，TNF-alpha [(6.1±2.9）pg/mL] and IFN-γ[(13.2±3.5）pg/mL] in the study group were significantly higher than those in the control group [(3.3±2.3）pg/mL，(4.6±2.4）pg/mL，(9.5±2.8）pg/mL]，the control group [(3.5±2.4）pg/mL，(4.9±2.6）pg/mL，(10.2±3.0）pg/mL]，respectively. The levels of IL-6 [(13.2±8.1）pg/mL] and IL-10 [(5.1±3.2）pg/mL] were significantly lower in control group [(18.2±6.9）pg/mL，(6.2±3.5）pg/mL] and control group [(17.3±7.0）pg/mL，(6.5±3.8）pg/mL] (P<0.05). The total incidence of toxic and side effects in the study group (21.4%) was significantly lower than that in the control group (57.1%) and the control group (42.9%) (P<0.05).　Conclusion　Pemetrexed combined with cisplatin and gefitinib in the treatment of non-small cell lung cancer can improve the level of T cell subsets and cytokines in patients with small cell lung cancer.

参考文献/References:

[1] 张朝巍.贝伐单抗与培美曲塞、顺铂联合治疗晚期肺腺癌的临床效果及对VEGF的影响[J].山东医药,2017，31(25):96-98. [2] 胡杨,杨玲,魏友英.培美曲塞联合吉非替尼对中老年晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].中国老年学杂志,2018,38(23):79-81. [3] 刘红柳,杨家梅.培美曲塞单药或联合吉非替尼治疗EGFR-TKI耐药后晚期非小细胞肺癌临床观察[J].中国癌症杂志,2017，39(2):60-64. [4] 王建芳,刘建江,孙彩萍，等.EGFR突变阴性肺腺癌寡转移培美曲塞联合顺铂同步化放疗序贯培美曲塞维持治疗临床观察[J].中华肿瘤防治杂志,2018,25(22):54-58. [5] Jones BS，Jerome MS，Miley D，et al. Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer[J]. Lung Cancer，2017，106(Complete):125-130. [6] 俞婷婷,卢喜,单莉.培美曲塞与依托泊苷联合顺铂同步胸部放疗治疗局部晚期肺腺癌的疗效和药物经济学比较研究[J].中国全科医学,2018，23(2):2871-2875. [7] 赵维勇,赵滑峰,王海静，等.培美曲塞二钠与吉非替尼对肺腺癌细胞的放射增敏作用[J].南京医科大学学报(自然科学版),2017，43(10):23-30. [8] Chen WQ，Li P，Wang Q，et al.A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma[J].Zhonghua zhong liu za zhi [Chinese journal of oncology]，2018，40(2):133-137. [9] 王兆峰，潘灏，易俊，等.非小细胞肺癌合并孤立性脑转移[J].医学研究生学报，2018，31(1):70-72. [10] 李元明,刘文博,李超，等.恩度联合培美曲塞治疗中晚期非小细胞肺癌临床疗效及对患者生活质量的影响[J].山东医药,2017，47(22):69-71. [11] 周毅,周健,张莹，等.培美曲塞联合奈达铂治疗晚期肺腺癌临床疗效及其安全性观察[J].第三军医大学学报,2018,40(13):1236-1241. [12] 李梅,耿一超,杨文刚，等.培美曲塞＋顺铂或多西他赛＋顺铂同期胸部IMRT治疗Ⅳ期肺腺癌的疗效和安全性[J].中华放射肿瘤学杂志,2018,27(6):564-569. [13] He Q，Bi X，Ren C，et al.Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases[J].Anticancer Res，2017，37(8):4711-4716. [14] 熊焕文,夏国际,吴冠楠.晚期肺腺癌患者Ki-67表达水平与临床疗效的关系[J].医学研究生学报,2018,31(12):55-58. [15] 邹子元,张小利,许信杰，等.基于LUX-Lung试验的阿法替尼在晚期非小细胞肺癌临床应用的研究进展[J].肿瘤,2017，17(7):129-134. [16] 徐升，张军宁，甘广辉.化疗联合调强放射治疗局部进展期非小细胞肺癌患者的疗效分析[J].医学研究生学报，2018，31(8):57-61. [17] 金珊珊,束永前.中晚期非小细胞肺癌患者培美曲塞联合铂类化疗前后免疫抑制细胞检测及意义[J].中华肿瘤防治杂志,2018,25(22):49-53. [18] 魏雪，叶胜兵，王璇，等.非小细胞肺癌甲醛固定石蜡包埋切片DNA再利用的可行性研究[J].医学研究生学报，2019，32(2):81-86.

相似文献/References:

[1]李子贺,骆益宙,黄凤林,等.长程小剂量顺铂联合射频透热治疗恶性消化道肿瘤82例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(03):248.
[2]胡丽花,赵嫦娥,宋成文.增敏化疗对宫颈癌同步放疗患者生存质量和免疫功能的影响研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):588.[doi:10.3969/j.issn.1672-271X.2021.06.006]
　HU Li-hua,ZHAO Chang-e,SONG Cheng-wen.Study on the effect of sensitization chemotherapy on the quality of life and immune function of patients with cervical cancer receiving concurrent radiotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(01):588.[doi:10.3969/j.issn.1672-271X.2021.06.006]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2020-01-06